These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection. Martiniano SL; Wagner BD; Levin A; Nick JA; Sagel SD; Daley CL Chest; 2017 Oct; 152(4):800-809. PubMed ID: 28483608 [TBL] [Abstract][Full Text] [Related]
3. Luo J; Yu X; Jiang G; Fu Y; Huo F; Ma Y; Wang F; Shang Y; Liang Q; Xue Y; Huang H Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760127 [TBL] [Abstract][Full Text] [Related]
4. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. Ferro BE; Meletiadis J; Wattenberg M; de Jong A; van Soolingen D; Mouton JW; van Ingen J Antimicrob Agents Chemother; 2016 Feb; 60(2):1097-105. PubMed ID: 26643335 [TBL] [Abstract][Full Text] [Related]
5. Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome. Kwak N; Whang J; Yang JS; Kim TS; Kim SA; Yim JJ Chest; 2021 Feb; 159(2):517-523. PubMed ID: 32712225 [TBL] [Abstract][Full Text] [Related]
6. The antimicrobial susceptibility of non-tuberculous mycobacteria. Cowman S; Burns K; Benson S; Wilson R; Loebinger MR J Infect; 2016 Mar; 72(3):324-31. PubMed ID: 26723913 [TBL] [Abstract][Full Text] [Related]
7. In Vitro Activity and Clinical Outcomes of Clofazimine for Nontuberculous Mycobacteria Pulmonary Disease. Kim DH; Kim BG; Kim SY; Huh HJ; Lee NY; Koh WJ; Kim H; Kwon OJ; Jhun BW J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640599 [TBL] [Abstract][Full Text] [Related]
8. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. van Ingen J; Totten SE; Helstrom NK; Heifets LB; Boeree MJ; Daley CL Antimicrob Agents Chemother; 2012 Dec; 56(12):6324-7. PubMed ID: 23027189 [TBL] [Abstract][Full Text] [Related]
9. Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin. Jarand J; Davis JP; Cowie RL; Field SK; Fisher DA Chest; 2016 May; 149(5):1285-93. PubMed ID: 26513209 [TBL] [Abstract][Full Text] [Related]
10. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327 [TBL] [Abstract][Full Text] [Related]
11. Novel Mutations Associated with Clofazimine Resistance in Mycobacterium abscessus. Chen Y; Chen J; Zhang S; Shi W; Zhang W; Zhu M; Zhang Y Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712660 [No Abstract] [Full Text] [Related]
12. Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection. Kunkel M; Doyle-Eisele M; Kuehl P; Rotermund K; Hittinger M; Ufer S; Reed M; Grant M; Hofmann T Antimicrob Agents Chemother; 2023 Feb; 67(2):e0114422. PubMed ID: 36648233 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. Mougari F; Loiseau J; Veziris N; Bernard C; Bercot B; Sougakoff W; Jarlier V; Raskine L; Cambau E; J Antimicrob Chemother; 2017 Jun; 72(6):1669-1677. PubMed ID: 28333340 [TBL] [Abstract][Full Text] [Related]
14. Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections. Banaschewski B; Verma D; Pennings LJ; Zimmerman M; Ye Q; Gadawa J; Dartois V; Ordway D; van Ingen J; Ufer S; Stapleton K; Hofmann T J Cyst Fibros; 2019 Sep; 18(5):714-720. PubMed ID: 31138497 [TBL] [Abstract][Full Text] [Related]
15. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Binder AM; Adjemian J; Olivier KN; Prevots DR Am J Respir Crit Care Med; 2013 Oct; 188(7):807-12. PubMed ID: 23927602 [TBL] [Abstract][Full Text] [Related]
16. Identification of Non-Tuberculosis Mycobacteria by Line Probe Assay and Determination of Drug Resistance Patterns of Isolates in Iranian Patients. Karami-Zarandi M; Bahador A; Gizaw Feysia S; Kardan-Yamchi J; Hasan-Nejad M; Mosavari N; Feizabadi MM Arch Razi Inst; 2019 Dec; 74(4):375-384. PubMed ID: 31939254 [TBL] [Abstract][Full Text] [Related]
18. Epidemiology and risk factors associated with NTM pulmonary and extrapulmonary infections in a high tuberculosis endemic Region. Wani SR; Wattal C; Raveendran R Indian J Med Microbiol; 2020; 38(2):169-175. PubMed ID: 32883930 [TBL] [Abstract][Full Text] [Related]
19. Trends in the Prevalence and Antibiotic Resistance of Non-tuberculous Mycobacteria in Mainland China, 2000-2019: Systematic Review and Meta-Analysis. Zhou L; Xu D; Liu H; Wan K; Wang R; Yang Z Front Public Health; 2020; 8():295. PubMed ID: 32850570 [No Abstract] [Full Text] [Related]
20. Activities of Dual Combinations of Antibiotics Against Multidrug-Resistant Nontuberculous Mycobacteria Recovered from Patients with Cystic Fibrosis. Schwartz M; Fisher S; Story-Roller E; Lamichhane G; Parrish N Microb Drug Resist; 2018 Oct; 24(8):1191-1197. PubMed ID: 29368988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]